Design Therapeutics (DSGN) Total Current Liabilities (2020 - 2026)

Design Therapeutics has disclosed Total Current Liabilities across 7 years of filings, most recently posting $10.2 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $10.2 million, up 23.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.2 million (up 23.73% YoY), and the FY2025 annual result was $13.1 million, up 54.28% from the prior year.
• Total Current Liabilities came in at $10.2 million for Q1 2026 at Design Therapeutics, down from $13.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $13.1 million in Q4 2025 to a low of $5.5 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $9.0 million (2023), against an average of $9.3 million.
• Across the five-year window, Total Current Liabilities surged 116.98% in 2022 and tumbled 47.3% in 2024, its largest moves.
• Design Therapeutics' Total Current Liabilities stood at $10.8 million in 2022, then slipped by 10.71% to $9.6 million in 2023, then decreased by 12.06% to $8.5 million in 2024, then jumped by 54.28% to $13.1 million in 2025, then fell by 21.95% to $10.2 million in 2026.
• The last three Total Current Liabilities figures came in at $10.2 million (Q1 2026), $13.1 million (Q4 2025), and $11.2 million (Q3 2025), per Business Quant data.